Business Description
AnaptysBio Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
AN6.GermanyANAB.Mexico0HFQ.UKANAB.USA Description
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.33 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.55 | |||||
| Beneish M-Score | 29.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 124.7 | |||||
| 3-Year EBITDA Growth Rate | 6.6 | |||||
| 3-Year EPS without NRI Growth Rate | 5.5 | |||||
| 3-Year FCF Growth Rate | 5 | |||||
| 3-Year Book Growth Rate | -10.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.27 | |||||
| 9-Day RSI | 53.8 | |||||
| 14-Day RSI | 50.39 | |||||
| 6-1 Month Momentum % | 39.08 | |||||
| 12-1 Month Momentum % | -2.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.39 | |||||
| Quick Ratio | 21.39 | |||||
| Cash Ratio | 21.03 | |||||
| Days Sales Outstanding | 77.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2680.13 | |||||
| Net Margin % | -3003.32 | |||||
| ROE % | -40.8 | |||||
| ROA % | -23.13 | |||||
| ROIC % | -102.98 | |||||
| ROC (Joel Greenblatt) % | -547.5 | |||||
| ROCE % | -20.68 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 160.37 | |||||
| PB Ratio | 2.64 | |||||
| Price-to-Tangible-Book | 2.64 | |||||
| EV-to-EBIT | -2.66 | |||||
| EV-to-Forward-EBIT | -2.86 | |||||
| EV-to-EBITDA | -2.71 | |||||
| EV-to-Forward-EBITDA | -2.88 | |||||
| EV-to-Revenue | 69.01 | |||||
| EV-to-Forward-Revenue | 19.13 | |||||
| EV-to-FCF | -3.5 | |||||
| Price-to-Net-Current-Asset-Value | 6.69 | |||||
| Price-to-Net-Cash | 7.17 | |||||
| Earnings Yield (Greenblatt) % | -37.59 |
